5-Nitrofuran-2-yl derivatives: Synthesis and inhibitory activities against growing and dormant mycobacterium species
摘要:
Eighteen 5-nitrofuran-2-yl derivatives were prepared by reacting 5-nitro-2-furfural with various (sub)phenyl/pyridyl thiosemicarbazide using microwave irradiation. The compounds were tested for their in vitro activity against tubercular and various non-tubercular mycobacterium species in log-phase and 6-week-starved cultures. Compound N-(3,5-dibromopyridin-2-yl)-2-((5-nitrofuran-2-yl) methylene) hydrazinecarbothioamide (4r) was found to be the most potent compound (MIC: 0.22 mu M) and was 3 times more active than standard isoniazid (INH) and equally active as rifampicin (RIF) in log-phase culture of Mycobacterium tuberculosis H37Rv. In starved M. tuberculosis H37Rv, 4r inhibited with MIC of 13.9 mu M and was found to be 50 times more active than INH and slightly more active than RIF. (C) 2008 Elsevier Ltd. All rights reserved.
5-Nitrofuran-2-yl derivatives: Synthesis and inhibitory activities against growing and dormant mycobacterium species
作者:Dharmarajan Sriram、Perumal Yogeeswari、Prathiba Dhakla、Palaniappan Senthilkumar、Debjani Banerjee、Thimmappa H. Manjashetty
DOI:10.1016/j.bmcl.2008.12.088
日期:2009.2
Eighteen 5-nitrofuran-2-yl derivatives were prepared by reacting 5-nitro-2-furfural with various (sub)phenyl/pyridyl thiosemicarbazide using microwave irradiation. The compounds were tested for their in vitro activity against tubercular and various non-tubercular mycobacterium species in log-phase and 6-week-starved cultures. Compound N-(3,5-dibromopyridin-2-yl)-2-((5-nitrofuran-2-yl) methylene) hydrazinecarbothioamide (4r) was found to be the most potent compound (MIC: 0.22 mu M) and was 3 times more active than standard isoniazid (INH) and equally active as rifampicin (RIF) in log-phase culture of Mycobacterium tuberculosis H37Rv. In starved M. tuberculosis H37Rv, 4r inhibited with MIC of 13.9 mu M and was found to be 50 times more active than INH and slightly more active than RIF. (C) 2008 Elsevier Ltd. All rights reserved.